Subsequently, many studies have tried to elucidate the mechanisms through which Sfrp5 and Wnt5a are associated with obesity and cardiometabolic risk factors, as well as their potential role in developing new pharmaceutical compounds. The gene discussed is SFRP5; the disease is obesity disorder.